Target intelligence / Profile preview

Immunoglobulin heavy diversity 4-23 (IGHD4-23)

Target
IGHD4-23
Molecular classification
Other (Immunoglobulin heavy chain diversity gene segment)
01

Overview

Immunoglobulin heavy diversity 4-23 (IGHD4-23) is a gene segment in the immunoglobulin heavy locus (IGH) encoding a portion of the antibody heavy chain variable region. It is classified as a diversity (D) gene segment, participating in V(D)J recombination, the process that generates diversity in the antigen-binding site of immunoglobulin molecules. IGHD4-23 is denoted as "non-functional" in the current Ensembl annotation and functions as a genetic component, not as a protein or therapeutic target. Diversity segments combine with variable (V) and joining (J) gene segments to form the variable region of immunoglobulins, shaping the specificity and diversity of the adaptive immune response[2][1][4]. IGHD genes like IGHD4-23 do not represent receptors or functional molecular targets themselves, but rather are essential DNA elements used during B cell development to generate antibody diversity. IGHD4-23 is not a protein, receptor, or drug target; it is a short DNA gene segment used in the assembly of immunoglobulin genes through recombination[2][1]. The gene is annotated as "non-functional" in the human genome (ENSEMBL: ENSG00000227196)[2]. The primary role is in immunogenetic diversity generation; not directly implicated as a biomarker, therapeutic target, or disease gene. There are no drugs or mechanisms of action targeting IGHD4-23, as it does not produce a functional protein on its own. The IGHD4-23 symbol and name are correct, but it is often misinterpreted as a true functional target or receptor, which is not the case.

Other names
IGHD423
02

Biological functions

Immune responseAdaptive immunity (specifically, contributes to antibody variable region diversity)
03

Disease associations

Other (contributes to immunoglobulin diversity, which influences immune responses and may indirectly impact susceptibility to infection, autoimmune disorders, and response to vaccines, but not a direct disease role)

Beyond the preview

Go deeper on Immunoglobulin heavy diversity 4-23 (IGHD4-23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy diversity 4-23 (IGHD4-23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call